| Autor: |
Butler KS; Department of Pathology, University of New Mexico, and Cancer Research and Treatment Center, Albuquerque, NM, USA., Lovato DM, Adolphi NL, Belfon R, Fegan DL, Monson TC, Hathaway HJ, Huber DL, Tessier TE, Bryant HC, Flynn ER, Larson RS |
| Jazyk: |
angličtina |
| Zdroj: |
Cell transplantation [Cell Transplant] 2013; Vol. 22 (10), pp. 1943-54. Date of Electronic Publication: 2012 Oct 12. |
| DOI: |
10.3727/096368912X657963 |
| Abstrakt: |
Organ transplantation is a life-saving procedure and the preferred method of treatment for a growing number of disease states. The advent of new immunosuppressants and improved care has led to great advances in both patient and graft survival. However, acute T-cell-mediated graft rejection occurs in a significant quantity of recipients and remains a life-threatening condition. Acute rejection is associated with decrease in long-term graft survival, demonstrating a need to carefully monitor transplant patients. Current diagnostic criteria for transplant rejection rely on invasive tissue biopsies or relatively nonspecific clinical features. A noninvasive way is needed to detect, localize, and monitor transplant rejection. Capitalizing on advances in targeted contrast agents and magnetic-based detection technology, we developed anti-CD3 antibody-tagged nanoparticles. T cells were found to bind preferentially to antibody-tagged nanoparticles, as identified through light microscopy, transmission electron microscopy, and confocal microscopy. Using mouse skin graft models, we were also able to demonstrate in vivo vascular delivery of T-cell targeted nanoparticles. We conclude that targeting lymphocytes with magnetic nanoparticles is conducive to developing a novel, noninvasive strategy for identifying transplant rejection. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
